)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Fulcrum Therapeutics
Fulcrum Therapeutics (FULC) investor relations material
Fulcrum Therapeutics M&A announcement summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.M&A announcement summary17 Aug, 2026
Deal rationale and strategic fit
Merger creates a leading migraine-focused biotech company, leveraging Slate's pipeline of next-generation therapeutics and expertise to address significant unmet needs in migraine treatment.
Strategic review identified this transaction as the optimal path for stockholder value and therapeutic advancement.
Financial terms and conditions
All-stock transaction with pre-merger Fulcrum stockholders owning 5%, Slate stockholders (including new investors) owning 95%, subject to adjustment.
$245 million oversubscribed private placement led by top healthcare investors, funding operations into 2029.
Fulcrum to contribute $20.3 million net cash and pay a $270 million special cash dividend to its pre-merger stockholders before closing.
Integration plans and timeline
Slate's CEO and senior management will lead the combined company, which will be renamed and trade as Slate Medicines on Nasdaq.
Slate's board of directors will serve as the board of the combined company.
Merger expected to close in Q4 2026, subject to stockholder approval and customary conditions.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Fulcrum Therapeutics
- A major R&D wind-down and pending Slate merger reshape the outlook and planned $275M dividend.FULC
Q3 2026 - Discontinued lead program, restructured operations, and reviewing strategic alternatives amid ongoing losses.FULCQ2 2026
- Pociredir Phase 1b readouts in sickle cell disease expected in 2025, with pipeline expansion underway.FULCLeerink’s Global Healthcare Conference 2025
- Director elections, executive pay, and auditor ratification headline the 2026 annual meeting.FULCProxy filing
- Stockholders will vote on director elections, executive pay, and auditor ratification.FULCProxy filing
- Pociredir demonstrated strong efficacy and safety in SCD, supporting advancement to late-stage trials.FULCCorporate presentation
- Pociredir showed strong efficacy and safety, with $333M cash runway supporting operations into 2029.FULCQ1 2026
- Pociredir achieved rapid, robust HbF increases and improved outcomes in sickle cell disease.FULC44th Annual J.P. Morgan Healthcare Conference
- Pivotal study planned after strong PIONEER data, with focus on sickle cell and U.S. launch.FULCLeerink Global Healthcare Conference 2026
Next Fulcrum Therapeutics earnings date
Q3 202618 Nov, 2026
Fulcrum Therapeutics
Next Fulcrum Therapeutics earnings date
Q3 202618 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to treat genetically defined rare diseases. The company leverages its proprietary product engine to identify and target genetic mechanisms underlying diseases. Fulcrum’s primary areas of focus include muscle and central nervous system disorders, with therapeutic candidates aimed at modulating gene expression to address the root causes of these conditions. The company is advancing its treatments through clinical trials, working to provide new options for patients with limited or no available therapies. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.